---
title: "Analyst Reaffirms Buy on Shattuck Labs, Maintains $17 Price Target on TL1A Pipeline Progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295569154.md"
description: "Needham analyst Joseph Stringer reaffirmed a Buy rating on Shattuck Labs with a $17 price target, citing TL1A pipeline progress. Key drivers include the planned Phase 2b Crohn’s trial in Q3 2026, encouraging Phase 1 data for SL-325, and validation from Merck’s successful TL1A studies. H.C. Wainwright also reiterated a Buy rating with a $14 target."
datetime: "2026-08-11T18:45:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295569154.md)
  - [en](https://longbridge.com/en/news/295569154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295569154.md)
generator: "portal-rs"
---

# Analyst Reaffirms Buy on Shattuck Labs, Maintains $17 Price Target on TL1A Pipeline Progress

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Shattuck Labs. The associated price target remains the same with $17.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Joseph Stringer has given his Buy rating due to a combination of factors tied to Shattuck Labs’ clinical progress and the broader TL1A landscape. He highlights management’s reaffirmed plan to initiate a Phase 2b Crohn’s disease trial in the third quarter of 2026, with 12‑week induction data expected in the first half of 2028, as a key value driver that supports a favorable long‑term risk‑reward profile.

Stringer also points to the encouraging Phase 1 healthy volunteer results for SL‑325 and notes that the recent share price recovery suggests investors are increasingly comfortable with the data. In addition, he views Merck’s successful TL1A studies in ulcerative colitis and hidradenitis suppurativa as validating Shattuck’s anti‑DR3 strategy, which he considers meaningfully differentiated, and therefore maintains an unchanged $17 price target alongside his Buy rating.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.

### Related Stocks

- [STTK.US](https://longbridge.com/en/quote/STTK.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [H.C. Wainwright Sticks to Its Buy Rating for Shattuck Labs (STTK)](https://longbridge.com/en/news/289068921.md)
- [Shattuck Labs Q2 net loss widens as R&D spending rises](https://longbridge.com/en/news/295520732.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [Lowe’s Earns Buy Rating as Strong Earnings and Cash Generation Offset Lower-End Guidance](https://longbridge.com/en/news/296383656.md)
- [Telsey Advisory Sticks to Their Buy Rating for Abercrombie Fitch (ANF)](https://longbridge.com/en/news/296366488.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**